Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

• US 6,358,939 B1
• Filed: 12/21/1999
• Issued: 03/19/2002
• Est. Priority Date: 12/21/1999
• Status: Expired due to Fees

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Northern Light Pharmaceuticals, LLC
• Inventors: Nashold, Faye E., Hayes, Colleen E.
• Primary Examiner(s): QAZI, SABIHA NAIM
• Application Number:
  US09/469,985
• Time in Patent Office: 819 Days
• Field of Search: 514/167, 552/653
• US Class Current: 514/167
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Methods of treating inflammatory bowel disease are described, and in particular the prevention and treatment of inflammatory bowel disease in humans as well as other animals. These methods involve the administration of biologically active vitamin D compounds, and therapeutic compositions thereof, so that the symptoms of Inflammatory Bowel Disease are reduced or relieved.

Claims

1. A method of treatment, comprising:

a) providing;

i) a subject with symptoms of an inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn'"'"'s disease, and

ii) a therapeutic composition comprising a biologically active vitamin D compound, wherein said biologically active vitamin D compound is 1,25-dihydroxyvitamin D₃; and

b) administering a therapeutically effective amount of said therapeutic composition to said subject under conditions such that said symptoms are reduced.

2. The method of claim 1, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μ

g and 20 μ

g per 160 pounds of said subject.

3. The method of claim 1, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μ

g and 10 μ

g per 160 pounds of said subject.

4. The method of claim 1, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μ

g and 10 μ

g per 160 pounds of said subject.

5. The method of claim 1, wherein said administering is conducted in a continuous manner.

6. The method of claim 1, wherein said administering is via a transdermal patch.

7. The method of claim 1, wherein said administering is via a suppository.

8. The method of claim 1, wherein said administering is via a slow release oral formulation.